BLCO (Bausch & Lomb) Other Current Liabilities: $771 Mil (As of Mar. 2026)


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $16.23
GF Value $18.46
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Bausch & Lomb Other Current Liabilities?

Bausch & Lomb BLCO -2.99% 77 Other Current Liabilities is $771 Mil as of Mar. 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.46 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Bausch & Lomb's other current liabilities for the quarter that ended in Mar. 2026 was $771 Mil.

Bausch & Lomb's quarterly other current liabilities increased from Sep. 2025 ($698 Mil) to Dec. 2025 ($737 Mil) and increased from Dec. 2025 ($737 Mil) to Mar. 2026 ($771 Mil).

Bausch & Lomb's annual other current liabilities increased from Dec. 2023 ($633 Mil) to Dec. 2024 ($657 Mil) and increased from Dec. 2024 ($657 Mil) to Dec. 2025 ($737 Mil).

Bausch & Lomb Other Current Liabilities Related Terms

Bausch & Lomb Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb Other Current Liabilities Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 608.00 538.00 633.00 657.00 737.00

Bausch & Lomb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 506.00 633.00 698.00 737.00 771.00
BLCO
77GF Score
Bausch & Lomb Corp BLCO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch & Lomb Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $771 Mil mean?
Bausch & Lomb (BLCO) has a Other Current Liabilities of $771 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bausch & Lomb.
Is Bausch & Lomb's Other Current Liabilities too high?
Bausch & Lomb's current Other Current Liabilities is $771 Mil. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Other Current Liabilities compare to ISRG and BDX?
Bausch & Lomb's Other Current Liabilities of $771 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bausch & Lomb. Bausch & Lomb's current Other Current Liabilities is $771 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.46, compared to a current price of $16.23 — trading 12.1% below its estimated fair value. The current Other Current Liabilities is $771 Mil. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Other Current Liabilities is $771 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $16.23 is trading 12.1% below its estimated GF Value™ of $18.46. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • Other Current Liabilities: $771 Mil
  • GF Value™: $18.46 vs. price of $16.23 (12.1% below fair value)
  • GF Score™: 77/100 with 9 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.23
Price
$18.46
GF Value